Pyrazinamide Dosing for Active Tuberculosis in Adults
For adults with drug-susceptible tuberculosis, pyrazinamide should be dosed at 15-30 mg/kg once daily (not exceeding 2 grams per day) for the initial 2 months of treatment. 1, 2
Standard Daily Dosing
The FDA-approved and guideline-recommended approach is:
- Daily dose: 15-30 mg/kg once daily
- Maximum daily dose: 2 grams (CDC recommendation) 1, 2
- Duration: Initial 2 months of a 6-month regimen 1, 2
- Administration: Once daily dosing is preferred over the older 3-4 divided dose regimens 2
Important caveat: While the FDA label states 3 grams should not be exceeded, the CDC recommendations specifically limit daily dosing to 2 grams maximum 1, 2. Follow the more conservative 2-gram limit for daily therapy.
Alternative Intermittent Dosing
If using twice-weekly directly observed therapy (DOT):
- Twice-weekly dose: 50-70 mg/kg (based on lean body weight) 1, 2
- Doses exceeding 3 grams twice weekly have been administered in studies without increased adverse reactions 2
- This regimen promotes compliance in outpatient settings 2
Thrice-weekly dosing is also an option but should be reserved for specific populations (HIV-negative patients at low risk of relapse with noncavitary or smear-negative disease) 1
Weight-Based vs. Flat Dosing Considerations
Recent high-quality evidence challenges traditional weight-banded dosing:
- Flat dosing at 1,000 mg daily may be superior to weight-banded dosing for optimizing therapeutic outcomes 3
- Body weight is not a clinically relevant predictor of pyrazinamide clearance 3
- Flat dosing of 1,000 mg would place more patients within the therapeutic window (231-355 mg·h/L) compared to current weight-banded approaches 3
- This represents the largest phase 3 randomized controlled trial data (2,255 participants) specifically examining pyrazinamide dosing 3
However, current official guidelines still recommend weight-based dosing, so flat dosing should be considered investigational until guidelines are updated 1, 2.
Critical Dosing Pitfalls
Obesity
- For obese patients (>20% above ideal body weight), consider dosing based on ideal body weight or modified ideal body weight: IBW + [0.40 × (actual weight – IBW)] 1
- Therapeutic drug monitoring may be warranted in obese patients 1
Renal Impairment
- No specific dose adjustment is provided in guidelines, but pyrazinamide half-life may be prolonged 2
- Monitor closely for toxicity
Hepatic Impairment
- Pyrazinamide is hepatically metabolized; half-life may be prolonged 2
- Elderly patients (>70 years) are at higher risk for drug-induced hepatitis 4
- Use with particular caution in older patients 4
Safety Monitoring
Hepatotoxicity is the primary concern:
- Occurs in approximately 3.9% of patients (grade 3 or higher liver function tests) 5
- Most commonly occurs within the first month of therapy 4, 6
- Drug-induced hepatitis is fully reversible when detected early 4
- The first 2 months of concomitant pyrazinamide use warrant particular safety attention 6
Other adverse effects:
- Hyperuricemia and arthralgia (may require discontinuation) 4
- Overall adverse event rate of approximately 21.4% in pediatric studies (likely similar in adults) 6
Pharmacokinetic-Pharmacodynamic Relationships
Higher pyrazinamide exposures correlate with better microbiological outcomes:
- Target AUC₀₋₂₄/MIC ratio: 209.08 for 90% maximal sterilizing effect 7
- Current recommended doses (15-30 mg/kg/day) achieve this target in only 15.1-53.3% of patients 7
- No relationship exists between pyrazinamide exposure and liver toxicity, suggesting higher doses may be safe 5
This pharmacokinetic data supports the potential for dose optimization, though clinical implementation awaits guideline updates 5, 3.
Special Populations
HIV co-infection:
- Use same dosing as HIV-negative patients 1, 8
- May require longer treatment courses overall (beyond 6 months) 2, 8
- Ensure ART initiation within 8 weeks of TB treatment 8
Pyridoxine supplementation:
- Always co-administer pyridoxine 25-50 mg daily with isoniazid (not specifically for pyrazinamide) 1